Mr. Turner has nearly 30 years of drug development and commercialization experience, leading multiple organizations through all phases of product development including the development of the final commercial drug process, method, facility, and process validations, all phases of clinical programs, numerous drug application filings and the transition and establishment of several critical commercialization processes. Prior to joining Vera, Turner served as the Chief Regulatory and Technical Operations Officer at Sierra Oncology, Inc. (acquired by GSK), overseeing regulatory affairs, quality assurance, technical operations, analytical development/quality control, and technical/medical writing. During this time, he prepared these functional areas for the expected commercial launch, as well as directed the compilation, review and filing of the U.S. New Drug Application (NDA) and European Marketing Authorization Application (MAA) for Ojjaara (momelotinib).
Prior to Sierra Oncology, Turner was Senior Vice President of Technical Operations and Regulatory Science at Aimmune Therapeutics (acquired by Nestlé) for several years culminating in the commercial launch of Palforzia, the first product approved to treat peanut allergy. Prior to his time at Aimmune, he served as Vice President of Regulatory Affairs and Global Quality at Dynavax Technologies Corporation as well as several years in a leadership position at MedImmune (now AstraZeneca). He has significant experience in both small molecule and biologic development and has led teams in multiple therapeutic areas including vaccinology, oncology, hematology, allergy and respiratory. Turner received his B.S. in Medical Microbiology with a minor in Chemistry from California State University at Long Beach.
What is William D. Turner's net worth?
The estimated net worth of William D. Turner is at least $1.83 million as of February 23rd, 2026. Turner owns 45,313 shares of Vera Therapeutics stock worth more than $1,833,817 as of February 27th. This net worth estimate does not reflect any other assets that Turner may own. Learn More about William D. Turner's net worth.
How do I contact William D. Turner?
Has William D. Turner been buying or selling shares of Vera Therapeutics?
In the last ninety days, William D. Turner has sold $91,810.26 in shares of Vera Therapeutics stock. Most recently, William D. Turner sold 2,187 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a transaction totalling $91,810.26. Following the completion of the sale, the insider now directly owns 45,313 shares of the company's stock, valued at $1,902,239.74. Learn More on William D. Turner's trading history.
Who are Vera Therapeutics' active insiders?
Vera Therapeutics' insider roster includes Robert Brenner (Insider), Patrick Enright (Director), Marshall Fordyce (Founder), Marshall Fordyce (CEO and Founder), Sean Grant (CFO), David Johnson (COO), Maha Katabi (Director), Beth Seidenberg (Director), Laurence Skelton (Insider), William Turner (Insider), and Joseph Young (CAO). Learn More on Vera Therapeutics' active insiders.
Are insiders buying or selling shares of Vera Therapeutics?
In the last year, Vera Therapeutics insiders bought shares 3 times. They purchased a total of 255,882 shares worth more than $5,527,583.36. In the last year, insiders at the sold shares 8 times. They sold a total of 48,490 shares worth more than $1,841,810.20. The most recent insider tranaction occured on February, 23rd when insider Robert Brenner sold 2,151 shares worth more than $90,298.98. Insiders at Vera Therapeutics own 16.3% of the company.
Learn More about insider trades at Vera Therapeutics. Information on this page was last updated on 2/23/2026.
